jRCT2021250053RecruitingNot Applicable
A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1) (J2S-MC-GZMK)
Not provided0 sites450 target enrollmentStarted: TBD
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 450
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
Eligibility Criteria
- Ages
- 18age old over to 55age old under (—)
- Sex
- All
Inclusion Criteria
- •Meet the diagnostic criteria of schizophrenia
- •Are on a stable standard of care medication regimen for schizophrenia
- •If the duration of illness is >6 years, participant has experienced at least one relapse of schizophrenia in last 3 years
- •Have at least 1 reliable study partner (for example, a family member, social worker, caseworker, residential facility staff, or nurse)
- •Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
- •self-inject study intervention store and use the provided study intervention as directed,
- •maintain electronic or paper study diaries, as applicable, and
- •complete the required questionnaires
Exclusion Criteria
- •Have lifetime history of bipolar disorder, borderline personality disorder, or any eating disorder
- •Evidence of moderate or severe substance or alcohol use disorder within 180 days of screening
- •Have type 1 diabetes, or history of ketoacidosis or hyperosmolar state or coma
- •Are actively suicidal or deemed to be a significant risk for suicide
- •Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
Investigators
Similar Trials
Recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis (VELOTA)Arthritis, PsoriaticjRCT2031250700240
Recruiting
Phase 4
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome2025-523355-59-00Qilu Pharmaceutical Co. Ltd.76
Recruiting
Phase 4
A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/kg) of LB-0702 and Nplate® in healthy volunteers.Not applicable (submitted trial is a bioequivalence study)2024-518285-27-00Laboratorio Reig Jofre S.A.34
Not yet recruiting
Phase 3
A clinical trial to study the effects of Brexpiprazole in comparison to Aripiprazole in patients suffering from Acute SchizophreniaSchizophrenia, unspecified,CTRI/2024/06/069258Torrent Pharmaceuticals Ltd.304
Not yet recruiting
Phase 3
A Study to assess Change in HbA1C levels and blood glucose levels and safety of Alkems Semaglutide Tablet compared to Rybelsus (Novo-nordisk semaglutide Tablet) in Type 2 Diabetes Mellitus after 24 weeksType 2 diabetes mellitus without complications,CTRI/2025/10/096183Alkem Laboratories Limited232
